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Background: Cystic ﬁbrosis (CF) can be a devastating disease. Disorders in essential fatty acid state are increasingly reported and various
supplementation trials have been performed in an attempt to improve outcomes. However, the mechanisms leading to these disturbances remain elusive.
We wanted to investigate the role of the diseased CF lung on fatty acid proﬁles.
Methods: We compared fatty acid proﬁles in patients with CF after lung transplantation (n=11) to age-matched healthy controls and homozygous
F508del patients (n=22 each).
Results: Compared to healthy controls, in patients with CF, there are decreased levels of docosahexaenoic, linoleic and arachidonic acid and
increased levels of mead acid. In patients that underwent a lung transplantation, levels of docosahexaenoic, linoleic and arachidonic acid were
normal. Mead acid did not decrease signiﬁcantly.
Conclusions: The diseased CFTR deﬁcient lung is a major determinant in the disturbed fatty acid proﬁle in CF.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Lung transplantation; Essential fatty acid; Poly-unsaturated fatty acid1. Introduction
Cystic fibrosis (CF) is the most frequent lethal genetic disorder
within the Caucasian race, with an incidence of 1 in 2500. Due to
the current medical treatment, the median survival of these
patients rose to 30–35 years. Pulmonary problems are the main
cause of death. In an effort to further improve care, more andmore
attention is paid to metabolic disturbances, as for instance diabetes
and also essential fatty acid (EFA) deficiency [1].
Abnormal FA profile has been reported in children with CF
since many years [2]. Renewed interest in this subject emerges
from the ability to influence FA profiles by supplements,
thereby adding to the dietary strategies to obtain an optimal
nutritional state [1]. Moreover, disturbances in fatty acid profiles⁎ Corresponding author at: Department of Pediatrics, Herestraat 49, 3000 Leuven,
Belgium. Tel.: +32 16 342004; fax: +32 16 343842.
E-mail address: Peter.witters@gmail.com (P. Witters).
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http://dx.doi.org/10.1016/j.jcf.2012.09.004have been implicated in the predisposition to lung disease [3].
Also, in a CF mouse model, supplementation of one of the FA
(docosahexaenoic acid (DHA, C22:6n−3) was beneficial to
the Pseudomonas endotoxin-enhanced lung inflammation, CF
pancreatic, ileal and liver disease [4,5]. Nevertheless, randomized
controlled trials are needed to confirm or deny beneficial effects
of EFA supplementation in patients with CF [1].
The major EFA defect in patients with CF seems to be an
increased release of arachidonic acid (AA, C20:4n−6), the most
important metabolic product of linoleic acid (LA) [6]. In serum as
well as in nasal and rectal biopsy samples, a high ratio of AA to
DHA is seen [7]. In addition there is a decrease in plasma levels
of linoleic acid (LA, C18:2n−6) and DHA) and a compensatory
increase in levels of eicosatrienoic acid (C20:3n−9) (also known
as mead acid (MA)) [1,8–10].
The aetiology of this abnormal fatty acid profile remains
obscure. Initially it was thought to result from fat malabsorption
linked to the exocrine pancreatic insufficiency. However, since itby Elsevier B.V. All rights reserved.
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hypothesis is less probable. It has been suggested that there is
a disturbance in essential fatty acid metabolism [12]. This
disturbance is related to the CF-genotype and minor changes in
the essential fatty patterns are even seen in CF-heterozygotes
[7,13].
Indisputably, lung disease is the most important aspect of CF.
There have been no trials (including a placebo group) showing
improvement or stabilization of lung function after improvement
of fatty acid state. Although lung function (measurement of the
forced expiratory volume in one second, FEV1) has been related
to CF fatty acid abnormalities [14] and as already stated, is
implicated in the predisposition of CF lung disease [3], its precise
relation is not clear. Moreover, interdependency of variables
(e.g. genotype, pancreatic state and lung function) poses a
problem to independently evaluate its relationship. Therefore,
instead of studying the influence of FA profile on lung disease,
we decided to study the reverse: the influence of removal of a
diseased CF lung on FA profile. We do this by comparing fatty
acid status in patients with CF and patients with CF that have
undergone a lung transplantation at least one year previously.2. Patients and methods
2.1. Patients
Plasma levels of fatty acids were determined in a group of
11 DF508/DF508 patients with CF who underwent a lung
transplantation at least one year before the onset of the study
(CF-transplant group). All patients were followed at the CF clinic
of the university hospital Gasthuisberg, (Leuven, Belgium). Ten
patients underwent a double lung transplantation, one patient a
single lung transplantation. This group was age-matched with
two DF508/DF508 patients with CF drawn from our cohort of
225 patients with CF (in an age-sorted patient list the preceding
and the following patient were selected, CF group). Additionally
we collected two healthy control samples per CF lung transplant
(again one older and one younger) (Control group). The plasma
fatty acid levels of these three groups were compared.
The study was approved by the local ethics committee and
(parental) informed consent was obtained for all patients.
At the time of the plasma fatty acid measurements, or as close
to as possible, following clinical information was retrieved from
the patients clinical files: age; age at diagnosis; gender; lung
function (FVC, FEV1 expressed as % predicted for sex, height
and age according to Knudson, within 3 months of the EFA
measurement); chronic Pseudomonas aeruginosa colonization
status (defined as repeated isolation of Pseudomonas aeruginosa
(at least 3 positive sputum samples, with at least 1 month interval
over at least a 6 month period [15]); weight, height, BMI and
their respective z-scores (using recent Flemish reference values);
serum vitamin E and cholesterol levels, dietary intake (daily
average for total caloric intake and fat intake calculated from
prospective 6 day written diary and fish intake during the last
2 months; number of fish meals/week); history of meconium
ileus. Pancreatic insufficiency was defined by the need forpancreatic enzyme supplements for the treatment of clinically
overt steatorrhea.
This study was approved by the local ethics committee and
(patient and/ or parental) informed consent was obtained for
all patients.
2.2. Plasma fatty acid determination
FA levels of the patients and controls were determined as
previously reported [16]. Hence, blood samples were drawn at
random times. Briefly, blood samples (5 mL on EDTA) were
centrifuged at 1000 g for 15 min at 4 °C. The plasma was
collected and stored at −80 °C for subsequent analysis. In glass
tubes containing 100 μL plasma, we added 20 μL of the internal
standard solution (providing 50 mg C19:0/L) and 2 mL of a
methanol/toluene (4/1, vol/vol) mixture. Samples were vortex-
mixed for 30 s, and we carefully added 200 μL acetyl chloride
dropwise while swirling the tubes. Tubes were capped under
nitrogen and transferred to a heating oven at 103 °C for 90 min.
After cooling, the tubes were uncapped, and samples were treated
by addition of 5 mL 6% K2CO3 and of 3 mL hexane. Recapped
tubes were vortex-mixed for 1 min and centrifuged for 7 min at
500 g. We collected the upper organic phase and repeated the
extraction procedure on the lower phase by adding 1 mL hexane.
The two upper combined phases were washed with 1 mL distilled
water, followed by a new centrifugation. The final organic phase
was collected and evaporated under nitrogen to dryness at 40 °C.
The dry residue was then redissolved in 200 μL hexane and
transferred to capped vials for further analysis.
Fatty acid methyl esters were separated by use of a gas
chromatograph (HP6890; Hewlett-Packard-Agilent) equipped
with a capillary column (DB-FFAP), 30 m by 0.25 mm ID by
0.25 μm (J and W Scientific, Agilent Technologies) and
identified and quantified by mass spectrometry (MS 5973;
Agilent Technologies). The temperature program was as
follows: initial at 130 °C with a 1-min hold; ramp: 4 °C/min
to 178 °C, 1 °C/min to 210 °C, and 40 °C/min to 245 °C with
a 7-min hold. Helium was used as carrier gas, under a flow rate
of 2.5 mL/min. We performed selected ion monitoring and
identified fatty acid methyl esters both by their respective
retention times and by comparison with spectra of pure
reference substances. Intra- and interassay CVs were b3%
and b5.7%, respectively (except for gamma-linolenate methyl
ester, with 9.3%).
2.3. Statistical analysis
SPSS 16.0 for windows (SPSS Inc., Chicago, IL, USA) was
used for statistical analysis. Demographic variables are expressed
as mean±standard deviatiation. As fatty acid levels were not
normally distributed, they are expressed as median (interquartile
range). For differences between two continuous variables in two
groups the Mann–Whitney U test (with exact correction if groups
were too small) was used. To compare categorical variables
Fisher's exact test (2-sided) was used. For correlations within a
group the Spearman Rank Correlation coefficient was used. A
p-valueb0.05 was considered statistically significant.
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3.1. Demographic variables (see Table 1)
All patients with CF were DF508 homozygous and had
pancreatic insufficiency. There were no differences between the
patients with CF with and without a lung transplantation
regarding age, sex, age at diagnosis, lung function, biometric
variables (height, weight and BMI z-score), fish intake or
history of meconium ileus. However transplanted patients had
decreased caloric intake (also decreased fat intake), higher
levels of serum cholesterol and vitamin E. All had been
chronically colonized with Pseudomonas auruginosa (contrary
to the non-transplanted group (14/22, see Table 1). Patients
who underwent a lung-transplantation did so 4.32±2.08 year
before the plasma FA determination.3.2. Analysis of fatty acids (see Table 2)
Total plasma fatty acid concentration was significantly
higher in lung transplanted patients.Table 1
Baseline characteristics.
Demographic variables are expressed as mean±standard deviation.
CF transplant
group
(n=11)
P-value
(TXvsCF)
CF group
(n=22)
Gender M/F 4/7 0.282 13/9
Age(y) 27.48±7.75 0.417 25.91±6.84
Age at diagnosis
(y)
2.326±2.702 0.069 3.312±7.815
Age at
transplantation
(y)
23.16±7.05 - Not
performed
Lung function FVC1
(%pred)
.80± .13 0.955 .79± .19
FEV1
(%pred)
.74± .20 0.105 .60± .23
Chronic Ps aer (n) 11
(pretransplant)
0.031 14
Biometrics Height
(z-score)
−1.22±0.93 0.316 −0.87±1.00
Weight
(z-score)
−1.15±1.00 0.806 −1.02±1.27
BMI
(z-score)
−0.52±0.70 0.720 −0.56±1.07
Dietary intake Kcal/d 2.381.82±
360.37
0.0003 2.985.68±
464.90
Fat (Kcal/d) 890.18±
204.57
0.0006 1.195.82±
205.63
Fish intake
(times/week)
0.95±0.61 0.509 0.77±0.67
History of
meconium
ileus
(n) 1 0.378 6
Serum cholesterol mg/dL 155.73±44.00 0.032 125.18±35.52
Serum vitamin E mg/dL 11.99±4.52 0.003 7.57±2.94
Bold = statistical significant.3.2.1. Saturated fatty acids
There were no differences between the patients with CF who
underwent a lung transplantation and the healthy controls, except
for Lignocerate (c24:0). These were decreased, however, not to
the extent as in the non-transplanted CF group. In the CF group,
levels of various unsatured fatty acids are significantly decreased
both compared to the control group as well as compared to the CF
transplant group (see Table 2).
3.2.2. Mono-unsaturated fatty acids
There were few differences between the groups. Only
Vaccenate (c18:1n−7) was higher in the CF transplant group
compared to the control group (not to the CF group) and
Palmitoleate (c16:1) was higher in the CF group compared to the
control group (not to the CF transplant group) (see Table 2).
3.2.3. Poly-unsaturated fatty acids (PUFA)
In the CF groups there was a significant decrease in DHA,
LA, AA compared to both the control group and the CF
transplant group. On the contrary these fatty acids were not
different between the CF transplant group and the control
group. MA was significantly increased in the CF group and also
in the CF transplant group compared to the control group. MA
was the only PUFA that was different between the control and
the CF transplant group (see Fig. 1.).
3.3. Relation between PUFA and other clinical variables
Within the CF group there was no difference with regard to
one of the four significantly changed PUFA levels (DHA, LA,
AA, MA) and Pseudomonas aeruginosa colonization (p≥0.05
for all), caloric intake, fat intake or vitamin E levels (p≥0.05
for all). However cholesterol levels were positively correlated
with absolute levels (expressed as μM) of DHA (r= .531),
LA(r= .528) and AA (r= .630).
Within the transplanted group there was the same significant
correlation between cholesterol and PUFA levels (DHA r= .838,
LA r= .752, AA r= .866), but also with the decreased fat intake
(AA r=− .656 and MA r=− .715). Vitamin E (which minimizes
DHA peroxidation [5]) also correlated positively with DHA level
(r= .636) (pb0.05 for all correlations).
3.4. Ratios between PUFAs (Table 3)
There was evidence for an essential fatty acid deficiency
(documented by an elevated ratio of MA to AA [11,14]) in
patients with CF (above the 0.02 cut-off) that was not present in
the CF transplant group. AA level multiplied by DHA level
(suggested as diagnostic marker for CF [16]) was decreased in
patients with CF, but not in CF lung transplanted patients. The
ratio of AA to DHA (a marker of inflammatory state and a
reflection of the n−6 to n−3 composition [7]) was not different
between the 3 groups although there was a trend to increased
values in patients with CF. The ratio of AA to dihomo-gamma
linoleic acid (DHGLA) (an indicator of Δ5-desaturase activity
[1]) was decreased in patients with CF, but not in the CF
transplant group (results in Table 3).
Table 2
Fatty acid levels of controls, patients with CF and CF lung transplanted patients.
(TX) Transplant
As fatty acid levels were not normally distributed, they are expressed as median (interquartile range).
Fatty acids (μM) Control TX CF Control versus
TX (p)
CF versus
TX (p)
CO versus
CF (p)
Lauric acid 6.92 14.58 3.93 0.26 0.23 0.59
(c12:0) (13.93) (30.93) (12.85)
Myristic acid 120.05 146.37 103.3 0.06 0.08 0.81
(c14:0) (103.98) (311.63) (106.58)
Hexadecanal dimethyl acetate 24.29 24.36 13.61 0.87 0.003 b0.001
(c16:0) (10.14) (15.64) (12.01)
Palmitic acid 1852.99 2671.18 1723.83 0.13 0.048 0.30
(c16:0) (1274.63) (2454.21) (832.58)
Stearic acid 617.19 618.76 488.98 0.90 0.06 0.008
(c18:0) (267.82) (393.57) (135.64)
Arachidic acid 18.56 16.29 10.38 0.38 0.024 b0.001
(c20:0) (8.47) (12.13) (3.67)
Behenic acid 49.72 45.01 28.82 0.09 0.040 b0.001
(c22:0) (15.85) (26.62) (8.18)
Lignoceric acid 39.27 34.08 20.1 0.04 0.012 b0.001
(c24:0) (14.55) (19.53) (6.49)
Myristoleic acid 2.58 2.00 2.38 0.81 0.90 0.65
(c14:1) (31.85) (21.67) (14.58)
Palmitoleic acid 153.22 316.58 277.24 0.17 0.96 0.024
(c16:1) (141.19) (312.71) (221.21)
Oleic acid 1672.74 2176.53 1558.23 0.07 0.05 0.94
(c18:1n−9) (1226.72) (2457.35) (661.81)
Vaccenic acid 136.87 198.66 151.74 0.011 0.08 0.39
(c18:1n−7) (65.91) (179.77) (95.87)
Eicosenoic acid 6.1 0 10.66 6.96 0.13 0.18 0.82
(c20:1n−9) (7.87) (25.14) (3.77)
Erucic acid 0.00 0.00 0.00 0.84 0.99 0.52
(c22:1n−9) (0.00) (0.17) (0.00)
Nervonic acid 77.68 76.84 73.82 0.96 0.32 0.12
(c24:1n−9) (39.79) (28.16) (19.93)
Alpha-Linolenic acid 48.07 61.61 32.48 0.49 0.08 0.06
(c18:3n−3) (49.29) (71.12) (28.5)
Eicosatrienoic acid n−3 0.00 0.00 0.00 0.69 0.69 1.00
(c20:3n−3) (0.00) (0.00) (0.00)
Eicosapentaenoid acid 54 47.97 55.77 0.87 0.81 1.00
(c20:5n−3) (40.52) (89.29) (32.78)
Docosatrienoic acid 0.00 0.00 0.00 1.00 1.00 1.00
(c22:3n−3) (0.00) (0.00) (0.00)
Docosapentaenoic acid n−3 28.91 33.32 29.52 0.34 0.34 0.85
(c22:5n−3) (16.95) (38.6) (25.54)
Docosahexaenoic acid 135.67 165.66 89.22 0.34 0.021 0.003
(c22:6n−3) (60.13) (113.87) (63.4)
Linoleic acid 2398.51 2172.24 1478.86 0.61 b0.001 b0.001
(c18:2n−6) (918.4) (930.35) (633.75)
Gamma-linolenic acid 26.19 28.38 27.18 0.72 0.82 0.34
(c18:3n−6) (24.22) (35.9) (30.69)
Dihomo-gamma-linolenic acid 121.66 150.75 119.63 0.38 0.26 0.77
(c20:3n−6) (95.53) (109.13) (70.38)
Arachidonic acid 561.84 682.6 444.38 0.67 0.015 0.021
(c20:4n−6) (322.29) (276.12) (185.39)
Docosatetraenoic acid 11.01 12.02 11.04 0.13 0.23 0.59
(c22:4n−6) (8.99) (15.72) (8.68)
Docosapentaenoic acid n−6 11.41 11.96 13.32 0.20 0.64 0.22
(c22:5n−6) (7.95) (32.86) (8.37)
Mead acid/eicosatrienoic acid n−9 8.41 23.56 29.91 0.014 0.32 b0.001
(c20:3n−9) (17.66) (41.19) (43.45)
Total 8327.04 10046.33 7009.9 0.26 0.02 0.06
(4981.21) (9056.46) (3081.33)
Bold = statistical significant.
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Fig. 1. Boxplots showing PUFA state in the three groups. Control group (left), CF group (middle), CF transplant group (right). Each dot represents an individual
measurement. Boxplot indicates the 25th, 50th and 75th centiles. The whiskers represent 1.5 and 3 times the interquartile range.
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In our small cohort of patients with CF we corroborate the
frequently observed changes in serum fatty acid profile in patients
with CF [1,8–14] confirming decreased levels of LA, AA, DHA
and increased levels of MA. The exact etiology of these changes
in plasma PUFA state in patients with CF remains unknown. In
this study, we compared a group of 11 lung transplanted patients
with CF with an age-matched, genotype matched (all pancreatic
insufficient) group of 22 patients with CF with comparable
biometric data and comparable fish intake and a healthy control
group. We demonstrated for the first time that after lung
transplantation there is a more normal fatty acid profile
(especially the poly-unsaturated fatty acids). Indeed, in all 11patients with CF (all DF 508) that underwent a lung transplan-
tation (longer than one year ago), the plasma levels of LA, AA
and DHA became comparable to healthy controls and MA levels
decreased toward more normal values.
The mechanisms leading to the abnormal PUFA profiles are
elusive. Numerous not mutually excluding hypotheses exist. In
the setup we used, we can partially break the interdepency of
pulmonary disease, pancreatic insufficiency and nutritional
state with regard to genotype. All patients were pancreatic
insufficient and remained so after lung transplant. So, decreased
uptake seems unlikely to be an explanation, which is in accordance
with previous findings in well-nourished patients with CF [11]. In
fact, the dietary intake was lower in the transplanted group despite
the better fatty acid profile.
Table 3
Ratios between selected fatty acids.
(TX) Transplant
As fatty acid levels were not normally distributed, they are expressed as median (interquartile range).
Median (IQR) Control TX CF Control versus
TX (p-value)
CF versus
TX (p-value)
Control versus
CF (p-value)
AA/DHA 4.57 4.02 6 0.218 0.063 0.057
(0.98) (1.81) (2.53)
AA×DHA 73446 109886 45697 0.486 0.009 0.004
(73553) (104449) (52034)
MA/AA 0.02 0.04 0.06 0.004 0.019 b0.001
(0.02) (0.03) (0.09)
AA/DHGLA 4.81 4.52 3.73 0.375 0.123 0.024
(2.65) (0.88) (1.31)
Bold = statistical significant.
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activity in CF [16] (which fits with our finding of lower AA/
DHGLA in non-transplanted patients with CF compared to
controls but could also be a sign of increased LA to AA
conversion [17]), increased use of fatty acids as a source of energy
[18] (which fits with the increased energy intake in patients with
CF compared to the transplanted patients although there was no
difference in nutritional state expressed as BMI z-score), increased
lipid turnover in membranes [19] and production of eicosanoids,
possibly related to an exacerbated inflammatory state [20].
Lung disease is the number one cause of death in CF and is
clinically the most important for the patient's well-being.
Therefore, we hypothesized that they could also play a central
role in the development of abnormal fatty acid profiles. Moreover,
there are some clues in this direction. Bronchoalveolar lavage fluid
of patients with CF contains more AA as compared to three control
groups (of healthy, chronic bronchitis patients, P. aeruginosa
infected patients without CF) [21]. Furthermore, CF-EFA
abnormalities have been related to FEV1 [14] and implicated in
the predisposition of CF lung disease [3]. Finally, in CF knockout
mice lipid imbalances were detected in CF regulated organs as for
instance in the lungs with decreased DHA levels and increased AA
levels [5]. DHA supplementation could also block Pseudomonas
endotoxin-enhanced lung inflammation [5].
By performing a lung transplantation, and thereby normalizing
PUFA state, we show that CF lungs are a major contributor to
abnormal fatty acid state. However, when performing a lung
transplantation, we induce three major changes: firstly, there is
possibly a dramatic change in inflammatory profile due to the
removal of a heavily infected and inflamed CF lung. This is
reflected by the observed decrease in AA/DHA ratio (Table 3).
Secondly, there is a functional CFTR present in the lung(s) of the
transplanted patients. Therefore, the CFTR status changes
partially, as 100% of the right cardiac output (in case of a double
lung transplantation) is exposed to the non-CF tissue (transplanted
lung) in the pulmonary circulation. Finally, all the secondary
effects of the diseased CF lung on various organs (e.g. mediated by
hypoxia), and of a lung transplantation (e.g. immunosuppression)
could also play a role. Unfortunately, in this observational study,
no distinction between these mechanisms can be made.
Several lines of evidence indicate a role for CFTR itself, in the
fatty acid metabolism. Firstly, the degree of PUFA impairment isindependently associated with the genotype group (mutation class)
[12]. Secondly, in some studies heterozygotes with almost no
inflammation have intermediate values between patients with CF
and healthy controls (7;13 and our own unpublished data). Thirdly,
other diseases with inflammation as upper respiratory tract disease
or asthma do not present with changes in the same magnitude as in
CF [7]. This was also the case in bronchoalveolar lavage fluid on
non-CF P. aeruginosa infected patients [21]. Fourthly, similar
PUFA changes in CF affected organs (lung, pancreas, ileum) have
been demonstrated in CFTR knock-out mice [5]. Finally, in cell
culture models, it was shown that CFTR dysfunction itself leads to
defective fatty acid composition (showing an increased conversion
form LA tot AA) [17]. Nevertheless, inflammation is capable of
changing PUFA composition [7], so it will probably also play a
role in this complex metabolic alteration.
In this article, we chose to report our data in the form of μM
rather thanmole%. This is because we believe any biological effect
modulated by the plasma is dependent on the concentration rather
than the relation to the total fatty acid level. Moreover, this makes it
more realistic, rather than just selecting fatty acids to calculate the
composition [22]. Of course, ratios between selected fatty acids
(Table 3) remain important and are unchanged by this. The within
group comparisons between cholesterol level or vitamin E and
DHA, LA, AA should however be interpreted with caution as there
is significant correlation of total FA and cholesterol and vitamin E.
A limitation to our study is the CF lung transplant patients are
not just patients with CF with healthy lungs. They all take
immunosuppressive medication which could have an effect on
fatty acid state. Nevertheless, that this effect would lead to
‘normalization’, apart form their effect on inflammation, seems
unlikely. Another limitation is that we chose tomeasure only total
plasma fatty acid levels. However, these have shown to have a
good relationship to lipid profiles in cell membranes of CF
affected tissue and those obtained in red blood cells [1,5,11].
Finally we did not measure EFA profile before and after
transplantation, so we can not really state that lung transplantation
reverses abnormalities in EFA profile. However, the existence
of a selection bias with patients with a better EFA profile
undergoing a lung transplantation seems unlikely.
To summarize, in this study we showed that the CF lung is
an important player in the development of abnormal fatty acid
profile. Rather than studying the effect of fatty acids on lung
228 P. Witters et al. / Journal of Cystic Fibrosis 12 (2013) 222–228function (as in EFA supplementation trial) we did the reverse
by documenting fatty acid profiles in a subset of patients with
CF who underwent lung transplantation. We showed that
post-transplant an evolution toward normal fatty acid profiles is
to be expected.
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